Strict Limits Urged on Use of Chimpanzees in US Biomedical, Behavioral Research

This recommendation includes the absence of any other applicable model and inability to perform ethically the research on people, according to a new report.

The report’s findings were published December 15, 2011, in a report from the Institute of Medicine (IOM; Washington DC, USA) of the US National Academies and National Research Council (Washington DC, USA). Moreover, use of these animals should be permitted only if relinquishing their use will prevent or considerably hinder developments necessary to prevent or treat life-threatening or debilitating disorders, according to the committee that wrote the report. Based on these criteria, chimpanzees are not necessary for most biomedical research.

The US National Institutes of Health (NIH; Bethesda, MD, USA) also should limit the use of chimpanzees in behavioral research to studies that provide otherwise unattainable insights into normal and abnormal behavior, mental health, emotion, or cognition, the report stated. The NIH should require these studies to be performed only on acquiescent animals using techniques that are minimally invasive and are applied in a way that minimizes pain and distress. Animals used in either biomedical or behavioral studies must be maintained in appropriate physical and social environments or in natural habitats, the report added.

“The report’s recommendations answer the need for a uniform set of criteria for assessing the scientific necessity of chimpanzees in biomedical, comparative genomics, and behavioral research,” said committee chair Jeffrey Kahn, senior faculty member, Johns Hopkins Berman Institute of Bioethics (Baltimore, MD, USA). “The committee concluded that research use of animals that are so closely related to humans should not proceed unless it offers insights not possible with other animal models and unless it is of sufficient scientific or health value to offset the moral costs. We found very few cases that satisfy these criteria.”

Advances in the development of other research tools and methods, including cell-based tests and other animal models, have rendered chimpanzees largely nonessential as research subjects, the committee noted. It acknowledged two possible ongoing uses: the development of a limited number of monoclonal antibody therapies already in the pipeline, and development of a vaccine that would prevent infection by hepatitis C virus (HCV).

New methods such as recombinant technologies can replace the chimpanzee in efforts to develop monoclonal antibodies. While industry and academic laboratories are in the process of adopting these alternate approaches, there may be a few therapies in development that require continued use of chimpanzees to keep progress from dithering and slowing patients’ access to needed new treatments. These cases should be assessed to ensure that they meet the criteria outlined in this report, and NIH should continue to support the development of and access to alternatives to make future use of chimpanzees unnecessary.

The committee did not reach a consensus decision on whether chimpanzees are essential to the development of a prophylactic HCV vaccine and if or how much the use of chimpanzees would accelerate or improve this work. Chimpanzees and humans are the only two species that are susceptible to HCV infection, and no other suitable animal models currently exist to test a prophylactic vaccine. However, chimpanzees’ immune systems clear HCV from their bodies more effectively, and they are less apt to develop liver damage. The committee members agreed that it would be possible and ethical to test a prophylactic vaccine candidate in humans without before testing in chimpanzees, provided that it was first shown to be safe and to trigger an immune response in other animals. However, the committee was evenly divided on the necessity of testing various HCV vaccine candidates in chimpanzees before proceeding to human trials.

Research to develop a therapeutic HCV vaccine--one that would be given to people already infected with HCV to boost their immune systems’ ability to clear the virus--and antiviral drugs for patients with chronic HCV infection can be performed without use of chimpanzees, the committee agreed. These products can be evaluated in people more readily and rapidly, and new drugs and therapeutic vaccine candidates are moving forward without the use of chimpanzees.

The committee would not close the door on the possibility that chimpanzees may be needed in future research to develop treatments or preventive strategies against as yet unknown diseases or disorders. It is impossible to know now whether other animal models or research tools will always serve successfully and rapidly enough in the face of a new health threat.

The report’s recommendations center on the scientific necessity of the chimpanzee as a research subject, but also take ethical issues into account. Chimpanzees’ genetic closeness to humans and their similar biologic and behavioral features not only make chimpanzees a uniquely valuable species for specific kinds of research but also demand greater justification for conducting research with them, the committee reported.

Related Links:
Institute of Medicine and National Research Council
Institute of Medicine
National Academies and National Research Council